Rosuvastatin and grapefruit
Pro Research Analysisby 
Searched over 200M research papers
Consensus Meter
Rosuvastatin and Grapefruit Juice Interaction
Introduction to Rosuvastatin and Grapefruit Juice
Rosuvastatin is a widely used statin for lowering cholesterol and preventing cardiovascular diseases. Grapefruit juice (GFJ) is known for its potential to interact with various medications, primarily through its effects on drug metabolism and transport mechanisms. Understanding the interaction between rosuvastatin and grapefruit juice is crucial for ensuring patient safety and effective medication management.
Mechanisms of Interaction: OATP2B1 and CYP3A4
Grapefruit juice can influence drug pharmacokinetics through several mechanisms, including the inhibition of cytochrome P450 3A4 (CYP3A4) and organic anion transporting polypeptides (OATP2B1). CYP3A4 is an enzyme responsible for the metabolism of many drugs, and its inhibition by GFJ can lead to increased drug bioavailability and potential toxicity. OATP2B1 is a transporter involved in the intestinal absorption of drugs, and its inhibition by GFJ can reduce drug absorption .
Rosuvastatin Pharmacokinetics and Grapefruit Juice
Studies have shown that grapefruit juice significantly reduces the exposure of rosuvastatin, indicating that rosuvastatin is a substrate for OATP2B1. This reduction in drug exposure suggests that GFJ can decrease the oral bioavailability of rosuvastatin, potentially diminishing its therapeutic efficacy.
Clinical Implications and Safety Concerns
Despite rosuvastatin not being primarily metabolized by CYP3A4, there are still significant clinical implications when combined with grapefruit juice. For instance, a case report highlighted the risk of rhabdomyolysis, a severe muscle breakdown condition, in a patient consuming pomegranate juice, which shares similar inhibitory effects on CYP3A4 as grapefruit juice. This suggests that even though rosuvastatin is not extensively metabolized by CYP3A4, the interaction with GFJ can still pose serious health risks.
Recommendations for Patients and Healthcare Providers
Given the potential for reduced drug efficacy and increased risk of adverse effects, it is advisable for patients on rosuvastatin therapy to avoid grapefruit juice. Healthcare providers should educate patients about the possible interactions and monitor for any signs of reduced drug effectiveness or adverse reactions.
Conclusion
The interaction between rosuvastatin and grapefruit juice primarily involves the inhibition of OATP2B1, leading to reduced drug absorption and potential therapeutic failure. Additionally, the risk of severe side effects like rhabdomyolysis, although rare, underscores the importance of avoiding grapefruit juice during rosuvastatin therapy. Patients and healthcare providers must be aware of these interactions to ensure safe and effective treatment outcomes.
Sources and full results
Most relevant research papers on this topic